Skip to main content
. 2016 Sep;24(9):1587–1595. doi: 10.1016/j.joca.2016.05.015

Fig. 1.

Fig. 1

Preventative muMab 911 attenuates OA pain behaviour but not cartilage damage or synovitis in the MIA model of OA pain. Rats received weekly subcutaneous injection of 10 mg/kg muMab 911 or PBS on days 0, 7, 14, and 21 post intra-articular injection of MIA or saline. Preventative muMab 911 robustly prevented MIA-induced changes in weight-bearing asymmetry (A, B) and attenuated hindpaw withdrawal thresholds (C, D). Statistical comparison of groups at each timepoint: two-Way ANOVA with Bonferroni's post-hoc tests, *P < 0.05, **P < 0.01, ***P < 0.001: MIA vs saline; #P < 0.05, ##P < 0.01, ###P < 0.001 muMab 911 vs PBS. Note saline muMab 911 group did not differ from the saline PBS group, and is not shown for clarity (n = 10 rats per group). Preventative treatment with muMab 911 did not significantly alter MIA-induced cartilage damage (n = 9–10 per group) (E) or synovial inflammation (n = 8–9 per group) (F). *P < 0.05, **P < 0.01, ***P < 0.001 vs saline-PBS. Comparisons between Areas Under Curve were performed using a Mann–Whitney U-test. Comparisons of histology between groups used a Kruskal Wallis test with Dunn's post hoc. A, C: data are mean ± SEM; B, D, E, F: data are median and interquartile range. M911: muMab 911.